Generated by AI
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings. The company’s current portfolio centers on nafamostat product candidates and pre-filled syringe products designed for acute care environments, including hospital and procedural settings. Its lead program, Niyad, is a lyophilized formulation of nafamostat being studied as a regional anticoagulant for the extracorporeal circuit, while its broader pipeline includes pre-filled syringe products such as ephedrine and phenylephrine formulations. Talphera serves healthcare providers by targeting needs in high-acuity care where reliable, ready-to-use therapies can support treatment workflows. Headquartered in San Mateo, California, Talphera remains focused on specialty pharmaceuticals for medically supervised use.
Website1850 Gateway Drive
San Mateo, CA, 94404
United States
The latest articles about TLPH.
Summary of Nov 13's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Investors talking about TLPH also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.